Core Insights - Eli Lilly's Omvoh shows significant improvements in bowel urgency for patients with moderately to severely active ulcerative colitis, with a 55% reduction in daily episodes by Week 12 and over half reduction in severity by Week 28 [1][2][3] Study Results - The Phase 3b LUCENT-URGE study is the first to assess bowel urgency through severity, frequency, and stool deferral time, capturing the full patient experience [1][9] - By Week 12, bowel urgency severity decreased by 52%, with the average Urgency Numeric Rating Scale (UNRS) score dropping from 6.9 at baseline to 3.3 at Week 28 [5] - Patients reported a 55% reduction in bowel urgency frequency, from 6.9 times per day at baseline to 3.1 at Week 12, maintained at Week 28 [5] - The proportion of patients able to delay restroom use for at least 15 minutes increased from 4.1% at baseline to 29.7% at Week 28 [5] Safety Profile - The safety profile of Omvoh in the study was consistent with previous trials, with 5.2% of patients reporting serious adverse events and 4.7% discontinuing treatment due to adverse events [3][4] Future Directions - Lilly is advancing combination studies of mirikizumab to enhance induction efficacy while maintaining long-term remission and safety [5][6] - Ongoing trials include the COMMIT-UC and COMMIT-CD studies, evaluating the efficacy of mirikizumab in conjunction with incretin-based therapies [6] Regulatory Status - Omvoh has received regulatory approvals for treating moderately to severely active ulcerative colitis and Crohn's disease in 45 countries [7][19]